KEY SUCCESS FACTORS IN PRECLINICAL DEVELOPMENT
Innovation drives the advancement of health care. Far from a random moment of inspiration, successful innovation follows a disciplined development path. Before new technologies can reach the clinic, careful planning to define and complete the right preclinical studies with the right models is vital to satisfy the needs of key stakeholders and propel the program to the next stage.
In this session, experts from IMMR, market leaders in the design and conduct of MedTech, Biopharma and Biotech preclinical studies in large models, explore the critical role of preclinical science in health care innovation.
What we will cover:
Nicolas Borenstein, DVM, PhD, Co-Founder and Scientific Director, IMMR
Luc Behr, DVM, PhD, Co-Founder and Scientific Director, IMMR
Laurence Fiette, DVM, PhD, DESAPV, HDR, Head of Pathology, IMMR
Robert Kieval, VMD, PhD, CEO, IMMR, Inc. (USA)
IMMR advances innovation and healthcare through its commitment to excellence in preclinical science.
With over 20 years of experience, IMMR sets an internationally recognized standard for the design and conduct of MedTech and Biotech preclinical studies in large models.
Products evaluated by IMMR have already been used to treat over one million patients. Located in Paris, IMMR provides unparalleled state-of-the-art, FDA-inspected facilities for completing sophisticated studies successfully and cost-effectively, with novel technologies including surgical implants, transcatheter therapies, surgical robotics, drug delivery and others.
IMMR’s services include early feasibility through to GLP studies, pathology evaluation and investigator training for human clinical trials. With world-leading expertise from first prototype to final regulatory studies, IMMR guides innovators through the entire preclinical process.